

Treatment of recurrent genotype 4 hepatitis C after liver transplantation: early virological response is predictive of sustained virological response. An AISF RECOLT-C Group Study

Francesca Romana Ponziani,* Alessandro Milani,* Antonio Gasbarrini,* Raffaella Zaccaria,*
Raffaella Viganò,[†] Maria Francesca Donato,[‡] Maria Cristina Morelli,[§] Lucia Miglioresi,^{||} Luisa Pasulo,[¶]
Maria Rendina,** Daniele Di Paolo,^{††} Maria Marino,^{‡‡} Pierluigi Toniutto,^{§§} Stefano Faggioli,^{¶¶} Maurizio Pompili*

* AISF RECOLT-C group: *Catholic University of Rome. Italy. [†] Niguarda Ca' Granda Hospital. Italy. [‡] Policlinico of Milan. Italy.
[§] Sant'Orsola Malpighi Hospital. Italy. ^{||} S. Camillo-Spallanzani Hospital. Italy. [¶] Ospedali Riuniti of Bergamo. Italy. ** University of Bari. Italy.
^{††} University of Rome Torvergata. Italy. ^{‡‡} University of Modena. Italy. ^{§§} University of Udine. Italy.

ABSTRACT

Introduction. Hepatitis C virus genotype 4 is predominant in the Middle East and Northern Africa, even if it has recently spread to Southern Europe. Data about the treatment of post-liver transplantation (LT) genotype 4 hepatitis C recurrence are scarce. We report a retrospective analysis of post-LT genotype 4 hepatitis C treatment in 9 Italian transplant centres, focusing on the overall survival rates and treatment outcome. **Results.** Among 452 recipients, we identified 17 HCV genotype 4 patients (16 males, 1 female) transplanted between 1998 and 2007. All patients received combined antiviral treatment with conventional doses of interferon (recombinant or pegylated) and ribavirin after histological diagnosis of hepatitis C recurrence. The observed overall survival after LT was 100% at 1 year and 83.3% at 5 years. More than 1/3 (35.3%) of patients achieved a sustained virological response (SVR) and 40% (data available in 15 subjects) an early virological response (EVR), which was significantly associated with the achievement of SVR (overall accuracy: 85.7%; predictive values of EVR absence/presence 80/88.8%; chi-square $p < 0.05$). **Conclusion.** In conclusion, in post-LT genotype 4 hepatitis C treatment, SVR rates are similar to genotype 1. Patients who don't show an EVR are not likely to achieve a SVR.

Key words. HCV recurrence. Liver transplantation. HCV treatment. Genotype 4. EVR.

INTRODUCTION

Hepatitis C virus (HCV) has 6 major genotypes and over 76 subtypes.^{1,2} Genotype 4 is widely prevalent in the Middle East and Northern Africa and is predominant in Egypt, where accounts for more than 90% of HCV infections.^{3,4} Genotype 4 HCV infection has a low prevalence in Europe, ranging between 0 and 19%, even if, in Mediterranean countries such as France, Spain, Greece and Italy, a trend towards an increasing prevalence has been recently observed.^{5,6} The main reasons for this phenomenon

appear to be the increased immigration from high prevalence areas and the diffusion among intravenous drug abusers.

Early reports have shown that patients with genotype 4 chronic hepatitis C respond as poorly as those with genotype 1 to conventional interferon (IFN) alpha and to combined IFN alpha plus ribavirin therapy.⁷⁻¹⁰ More recently, a few trials on the treatment of genotype 4 chronic hepatitis C using pegylated (PEG) IFN alpha 2b or alpha 2a plus ribavirin have been published, reporting highly variable rates of sustained virological response (SVR), ranging from 33 to 69%.¹¹⁻¹⁷ On the whole, the SVR rate of patients with chronic genotype 4 hepatitis C treated with PEG-IFN plus ribavirin seems to be slightly higher than that observed for genotype 1 (42–46%), but lower than that observed for genotypes 2 and 3 (76–82%).^{18,19} Furthermore, recent data suggest that, in genotype 4 patients, the achievement of a rapid virological response (RVR).^{14,20} or an early virological response (EVR)²¹ may be highly predictive of a subsequent SVR; moreover, a higher

Correspondence and reprint request: Dr. Francesca Romana Ponziani, M.D.
UOC Internal Medicine and Gastroenterology
Policlinico A. Gemelli,
Catholic University of Rome. Largo A. Gemelli 8 00168, Rome-Italy.
Ph.: +39-347-1227242/ +39-06-30156018
E mail: francesca.ponziani@yahoo.it

Manuscript received: October 17, 2011.
Manuscript accepted: November 01, 2011.

SVR rate can be observed in Egyptian patients compared to matched European patients.¹⁵

Only a few data about the clinical course and the treatment outcome of patients with genotype 4 chronic hepatitis C recurrence after liver transplantation (LT) are still currently available, especially in Europe.

The aim of this study is to retrospectively evaluate the effectiveness of the antiviral treatment in an Italian multicentric cohort of patients with genotype 4 chronic hepatitis C recurrence after LT.

MATERIAL AND METHODS

Seventeen patients (16 males and 1 female) aged from 39 to 59 years and affected by genotype 4-related chronic hepatitis C recurrence after LT were enrolled in the study. Five of them were native to Egypt, the remainders were Caucasian. All patients were followed-up in 9 Italian Transplant centres, during the period 1996-2010; and the time between LT and the clinical recurrence of hepatitis C ranged from 4 to 67 weeks (mean 25.1 weeks). None of the investigated patients had experienced a pre-LT treatment for HCV infection.

The outstanding clinical characteristics of the investigated patients are summarized in table 1.

The quantitative value of pre-treatment HCV-RNA was available in 14 out of 17 patients (mean vi-

remia 2.423.235 IU/mL, range 234-7.692.307 IU/mL), and a high viral load (more than 600.000 IU/mL) was detected in 7/14 cases. In the remaining 3 patients, transplanted before 2000, only a positivity for serum HCV-RNA was available.

Hepatocellular carcinoma (HCC) before LT was diagnosed in five patients (29.4%).

Patients were treated with conventional doses of recombinant (2 cases) or PEG-IFN (15 cases) alpha plus ribavirin for a scheduled period of 48-weeks.

RESULTS

The main results of the study are shown in table 1. We did not find any significant difference in the immunosuppressive regimen scheduled for these patients, since 8 received cyclosporine, 8 tacrolimus and 1 rapamcycine as the main immunosuppressive agent. The mean donor age was 46.6 (16-86 yrs); donors were 9 males and 8 of females; a donor-recipient gender mismatch was present in 7 case, always of the type female donor in male recipient.

Antiviral treatment duration was of at least 24 weeks in 14 subjects (82.3%), and 8 of them (47%) completed a standard 48-week course of treatment. Three patients received less than 24 weeks of antiviral treatment; in particular, patient n. 4 withdrew the treatment at week 16 for urgent abdominal sur-

Table 1. Demographic and clinical features of the 17 investigated patients.

Pts	Sex	Ethnicity	Age at LT (years)	HCC genotype	HCV	Grading †	Staging †	Pre-treatment viremia (IU/mL)	EVR	Treatment duration (weeks)	SVR
1	M	Eg	49	Yes	4*	10	1	Positive	No	52	Yes
2	M	Eg	44	No	4*	6	3	Positive	No	51	No
3	M	Eg	44	No	4*	8	2	Positive	No	48	No
4	M	Eg	47	Yes	4	14	2	1.687	Yes	16*	No
5	M	Ca	39	No	4c/4d	7	1	756.100	No	32	No
6	M	Ca	48	No	4a/4c	11	1	6.990.000	Yes	12	Yes
7	M	Ca	46	No	4	10	6	480.089	Yes	50	No
8	M	Ca	46	No	4	6	1	132.045	Yes	52	Yes
9	M	Ca	54	No	4	4	3	6.686.247	No	46	No
10	M	Ca	59	No	4c/4d	2	2	6.400.000	No	44	No
11	M	Ca	36	No	4c/4d	4	5	2.860.000	Yes	48	Yes
12	F	Ca	52	No	4c/4d	5	4	563.000	No	32	No
13	M	Ca	41	No	4c/4d	4	1	234	No	38	No
14	M	Eg	56	Yes	4	13	4	102.424	Yes	52	Yes
15	M	Ca	49	No	4	8	1	29.264	No	12	No
16	M	Ca	45	Yes	4d	6	1	961.538	No	36*	No
17	M	Ca	43	Yes	4	6	1	7.692.307	Yes	35	Yes

*Non-Pegylated IFN. †According to Ishak score. M: male. F: female. Eg: Egyptian. Ca: Caucasian. HCC: hepatocellular carcinoma. EVR: early virologic response. SVR: sustained virologic response.

gery due to laparocoele, while patients n. 6 and n. 15 suspended the treatment after 12 weeks for personal choice and for severe anemia, respectively. Six patients withdrew the treatment after 24 weeks, for the occurrence of neuropsychiatric symptoms, severe neutropenia, cholangitis, hepatocellular carcinoma recurrence and, finally, in two cases, lack of virological response.

A SVR was achieved in more than one third (35.3%) of the investigated patients, with a negative HCV-RNA persisting for at least 3 years (long term response) in all of them.

An EVR was achieved in 7 out of the 17 patients (41.1%). In the 14 patients who completed at least 24 weeks of treatment, we could also assess the ability of EVR in predicting the occurrence of SVR; 80% (4/5) of the patients exhibiting an EVR achieved a SVR, while it occurred in only one patient without EVR. In this way, EVR was significantly associated with the occurrence of SVR (overall accuracy: 85.7%; predictive values of EVR absence/presence 80/88.8%; chi-square $p < 0.05$).

Interestingly, one of the 3 patients who did not complete a 24-week course of treatment (Table 1, patient n. 6), achieved an EVR together with a SVR.

The observed overall survival rates (Kaplan-Meier method) were 100% at 1 year and 83.3% at 5 years after LT. No significant differences were found among the survival rates of patients with or without SVR, probably due to the low number of investigated subjects.

DISCUSSION

End stage HCV-related liver cirrhosis is the most common indication for LT in Europe.²² However, HCV reinfection of the graft occurs almost universally, leading to graft cirrhosis within 5 years after LT in 10-30% of recipients and to an impaired survival.²³ At present, the gold-standard of antiviral therapy is the combination of PEG-IFN plus ribavirin, administered, in most centres, after the histological diagnosis of infection recurrence in the graft. However, the reported SVR rates that could be achieved with the combined treatment are significantly lower than 50%, least of all in genotype 1 patients.²⁴⁻²⁶

Similarly to immunocompetent subjects with chronic hepatitis C, SVR rates in transplanted patients are significantly lower in genotypes 1 and 4 (25-40%) than in genotypes 2 and 3 (53-76%).²⁴⁻²⁹ Despite the increasing diffusion of genotype 4 HCV in the Mediterranean countries, only a few data

about its response to antiviral treatment after LT are available so far.⁴ Selzner, *et al.*²⁴ treated with conventional or PEG-IFN 119 patients with genotype 1 and 4 recurrent hepatitis C after LT; SVR was achieved in 40% of cases but no data about the response of the 9 patients with genotype 4 HCV infection were reported. Similarly, Jimenez-Perez, *et al.*³⁰ reported a 41% rate of SVR in 41 patients transplanted for recurrent hepatitis C; only in 4 cases graft reinfection was due to HCV genotype 4, but no data about their response to treatment were provided. The only available literature series specifically concerning transplanted patients with recurrent genotype 4 chronic hepatitis C is those published by Mudawi, *et al.*,³¹ who treated 17 patients from Saudi Arabia with a 48-week course of PEG-IFN alpha 2a plus ribavirin, achieving a SVR in 7 of them (41%) and Al-Hamoudi, *et al.*,³² who treated 25 patients from Saudi Arabia with a 48-week course of PEG-IFN alpha 2a plus ribavirin, achieving a SVR in 14 of them (56%).

Therefore, our study, despite the small number of enrolled patients, represents to our knowledge the largest available series in Europe regarding post-LT genotype 4 recurrent hepatitis C antiviral treatment.

According to the rates reported in patients with genotype 1, a SVR was achieved in 35.3% of our patients with recurrent genotype 4 chronic hepatitis C. Overall, EVR was able to predict the occurrence of SVR ($p < 0.05$) in 80% of patients with more than 24 weeks of therapy, while, in absence of EVR, a SVR was achieved only in one case. The SVR rate reported by our study is lower than that reported by Al-Hamoudi, *et al.*,³³ mainly because the authors excluded difficult-to-treat patients (those who failed previous pre- or post-transplant treatment, with renal failure, and pretreatment cytopenia), reporting only one case of treatment withdrawal. Moreover, in immunocompetent patients, Egyptian origin has been reported to be associated to higher SVR probabilities. Although the number of our transplanted patients is too low to draw any firm conclusion, we were not able to find a statistical difference (Chi-square 0.07; 1 d.f.) between SVR rates among Egyptian patients (40%) and the Italian ones (33.3%) (Table 1).

It is well known that, in immunocompetent subjects with genotype 1 chronic hepatitis C, the absence of EVR is a very strong predictor of treatment failure, since more than 90% of patients who do not reach EVR fail to achieve SVR.³³ Some recent papers confirmed the relevance of EVR in predicting a sub-

sequent SVR also in transplanted patients undergoing antiviral treatment for recurrent hepatitis C, mostly genotype 1-related.^{24,25,28} Al-Hamoudi, *et al.*,³² also confirmed that the probability of achieving SVR was related to achieving a negative HCV RNA at week 12. Our experience supports this evidence also in genotype 4 transplanted patients; therefore, in the subgroup of genotype 4 patients treated after liver transplantation who do not achieve an EVR, treatment discontinuation may be considered.

Literature data highlight that, independently from HCV genotype, the achievement of SVR seems to improve significantly the long term survival of patients with post-LT recurrent hepatitis C undergoing antiviral treatment.^{27,34} However, our series cannot support these data, since we were not able to find a statistical difference between the cumulative survival of subjects with or without SVR, probably due to the relatively low number of investigated patients. Furthermore, we included in our retrospective multicentric series only genotype 4 patients who were treated for HCV gen 4 recurrence after liver transplantation. Unfortunately, due to the study design, we were not able to collect data about those patients who did not receive the treatment, either due to mild hepatitis C recurrence or to contraindications to combined antiviral treatment. Therefore, we cannot provide any comparison regarding survival of these two groups.

As a last consideration, a recent meta-analysis reported that more than 84% of Egyptians with HCC are positive for genotype 4 HCV.³⁵ In our series, HCC was diagnosed in five patients (29.4%) and three of them were Egyptians. Then, HCC was present in 3 out of 5 Egyptian patients (60%) and in only 2 out of 12 Caucasians (16.7%). In particular, one of the 5 patients with HCC achieved a SVR but died 8 months after the end of the antiviral treatment due to HCC recurrence. However, in the other 4 cases, no HCC recurrence was observed. However, the small number of patients included in our retrospective series does not allow us to draw any epidemiological conclusion.

CONCLUSION

In conclusion, our study shows that transplanted patients with genotype 4 recurrent hepatitis C undergoing antiviral treatment achieve SVR in about one third of cases, and that EVR is a strong predictor of subsequent SVR.

REFERENCES

1. Simmonds P. Viral heterogeneity of the hepatitis C virus. *J Hepatol* 1999; 31: 54-560.
2. Simmonds P, Buck J, Combet C, et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. *Hepatology* 2005; 42: 962-73.
3. Kamal SM, Imad AN. Hepatitis C genotype 4: what we know and what we don't yet know. *Hepatology* 2008; 47: 1371-83.
4. Khattab MA, Ferenci P, Hadziyannis SJ, et al. Management of hepatitis C virus genotype 4: recommendations of an international expert panel. *Hepatology* 2011; 54: 1250-62.
5. Ansaldo F, Bruzzone B, Salmasso S, Rota MC, Durando P, Gasparini R, Icardi G. Different seroprevalence and molecular epidemiology patterns of hepatitis C virus infection in Italy. *J Med Virol* 2005; 76: 327-32.
6. Antaki N, Craxi A, Kamal SM, Moucari R, Van der Merwe S, Haffar S, Gadano A, et al. The neglected hepatitis C virus genotypes 4, 5 and 6: an international consensus report. *Liver Int* 2009; 10: 335-42.
7. El-Zayadi A, Simmonds P, Dabbous H, Prescott L, Selim O, Ahdy A. Response to interferon-alpha of Egyptian patients infected with hepatitis C virus genotype 4. *J Viral Hepat* 1996; 3: 261-4.
8. El-Zayadi A, Selim O, Haddad S, Simmonds P, Hamdy H, Badran HM, Shawky S. Combination treatment of interferon alpha-2b and ribavirin in comparison to interferon monotherapy in treatment of chronic hepatitis C genotype 4 patients. *Ital. J Gastroenterol Hepatol* 1999; 31: 472-5.
9. Kamal SM, Madwar MA, Peters T, Fawzy R, Rasenack J. Interferon therapy in patients with chronic hepatitis C and schistosomiasis. *J Hepatol* 2000; 32: 172-4.
10. Koshy A, Mada JP, Marcellin P, Martinot M. Treatment of hepatitis C virus genotype 4-related cirrhosis: Ribavirin and interferon combination compared with interferon alone. *J Clin Gastroenterol* 2002; 35: 82-5.
11. Alfaleh FZ, Hadad Q, Khuroo MS, Aljumah A, Algamed A, Alashgar H, Al-Ahdal MN, Mayet I, Khan MQ, Kessie G. Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C in Saudi patients commonly infected with genotype 4. *Liver Int* 2004; 24: 568-74.
12. Hasan F, Asker H, Al-Khalidi J, Siddique I, Al-Ajmi M, Owaid S, Varghese R. Peginterferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4. *Am J Gastroenterol* 2004; 99: 1733-7.
13. Kamal SM, El Tawil AA, Nakano T, He Q, Rasenack J, Hakam SA, Saleh WA, et al. Peginterferon {alpha}-2b and ribavirin therapy in chronic hepatitis C genotype 4: Impact of treatment duration and viral kinetics on sustained virological response. *Gut* 2005; 54: 858-66.
14. Kamal SM, El Kamary SS, Shardell MD, Hashem M, Ahmed IN, Muhammadi M, Sayed K, et al. Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: The role of rapid and early virologic response. *Hepatology* 2007; 46: 1732-40.
15. Roulot D, Bourcier V, Grando V, Deny P, Baazia Y, Fontaine H, Bailly F, et al; Observational VHC4 Study Group. Epidemiological characteristics and response to peginterferon plus ribavirin treatment of hepatitis C virus genotype 4 infection. *J Viral Hepat* 2007; 14: 460-67.
16. El Makhzangy H, Esmat G, Said M, Elraziky M, Shouman S, Refai R, Rekecewicz C, et al. Response to pegylated interferon alfa-2a and ribavirin in chronic hepatitis C genotype 4. *J of Med Vir* 2009; 81: 1576-83.

17. Elefsiniotis IS, Pavlidis C, Dimitroulopoulos D, Vezali E, Mihas C, Mariolis-Sapsakos T, Koutsounas S, Paraskevas E, Saroglou G. Differential viral kinetics in treated genotype 4 chronic hepatitis C patients according to ethnicity. *J Viral Hepat* 2009; 16: 738-42.
18. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. *Lancet* 2001; 358: 958-65.
19. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr., Haussinger D, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. *N Engl J Med* 2002; 347: 975-82.
20. Ferenci P, Laferl H, Sherzer TM, Gschwantler M, Maieron A, Brunner H, Stauber R, et al; Austrian Hepatitis Study Group. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. *Gastroenterology* 2008; 135: 451-8.
21. Elefsiniotis IS, Vezali E, Mihas C, Saroglou G. Predictive value of complete and partial early virological response on sustained virological response rates of genotype-4 chronic hepatitis C patients treated with PEG-interferon plus ribavirin. *Intervirolgy* 2009; 52: 247-51.
22. Adam R, McMaster P, O'Grady JG, Castaing D, Klempnauer JL, Jamieson N, Neuhaus P, et al. Evolution of liver transplantation in Europe: report of the European Liver Transplant Registry. *Liver Transpl* 2009; 12: 1231-43.
23. Berenguer M. What determines the natural history of recurrent hepatitis C after liver transplantation? *J Hepatol* 2005; 42: 448-56.
24. Selzner N, Renner EL, Selzner M, Adeyi O, Kashfi A, Therapondos G, Nigel Girgrah N, et al. Antiviral treatment of recurrent hepatitis C after liver transplantation: predictors of response and long-term outcome. *Transplantation* 2009; 88: 1214-21.
25. Lodato F, Berardi S, Gramenzi A, Mazzella G, Lenzi M, Morelli MC, Tame MR, et al. Clinical trial: peg-interferon alfa-2b and ribavirin for the treatment of genotype-1 hepatitis C recurrence after liver transplantation. *Aliment Pharmacol Ther* 2008; 28: 450-7.
26. Cescon M, Grazi GL, Cucchetti A, Vetrone G, Ravaioli M, Ercolani G, Morelli MC, et al. Predictors of sustained virological response after antiviral treatment for hepatitis C recurrence following liver transplantation. *Liver Transpl* 2009; 15: 782-9.
27. Berenguer M, Palau A, Aguilera V, et al. Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation. *Am J Transplant* 2008; 8: 679-87.
28. Berenguer M, Aguilera V, Prieto M, Rayón JM, Juan FS, Prieto M. Worse recent efficacy of antiviral therapy in liver transplant recipients with recurrent hepatitis C: impact of donor age and baseline cirrhosis. *Liver Transpl* 2009; 15: 738-46.
29. Dinges S, Morard I, Heim M, Dufour JF, Müllhaupt B, Giotra E, Clavien PA, Mentha G, Negro F; Swiss Association for the Study of the Liver (SASL 17). Pegylated interferon-alpha2a/ribavirin treatment of recurrent hepatitis C after liver transplantation. *Transpl Infect Dis* 2009; 11: 33-9.
30. Jiménez-Pérez M, Sáez-Gómez AB, Pérez-Daga JA, Lozano-Rey JM, De la Cruz-Lombardo J, Rodrigo-López JM. Hepatitis C virus recurrence after liver transplantation: analysis of factors related to sustained viral response. *Transplant Proc* 2010; 42: 666-8.
31. Mudawi H, Helmy A, Kamel Y, Al Saghier M, Al Sofayan M, Al Sebayed M, Khalaf H, et al. Recurrence of hepatitis C virus genotype-4 infection following orthotopic liver transplantation: Natural history and predictors of outcome. *Ann Saudi Med* 2009; 29: 91-7.
32. Al-Hamoudi W, Mohamed H, Abaalkhail F, Kamel Y, Al-Masri N, Allam N, et al. Treatment of genotype 4 hepatitis C recurring after liver transplantation using a combination of pegylated interferon alfa-2a and ribavirin. *Dig Dis Sci* 2011; 56: 1848-52.
33. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. *Hepatology* 2009; 49: 1335-74.
34. Picciotto FP, Tritto G, Lanza AG, Addario L, De Luca M, Di Costanzo GG, Lampasi F, et al. Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation. *J Hepatol* 2007; 46: 459-65.
35. Lehman EM, Wilson ML. Epidemiology of hepatitis viruses among hepatocellular carcinoma cases and healthy people in Egypt: a systematic review and meta-analysis. *Int J Cancer* 2009; 124: 690-7.